title: Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
abstract: The development of a vaccine against dengue faces unique challenges, including the complexity of the immune responses to the four antigenically distinct serotypes. Genome-wide transcriptional profiling provides insight into the pathways and molecular features that underlie responses to immune system stimulation, and may facilitate predictions of immune protection.
  
  
  
  In this study, we measured early transcriptional responses in the peripheral blood of cynomolgus macaques following vaccination with a live, attenuated tetravalent dengue vaccine candidate, TDV, which is based on a DENV-2 backbone. Different doses and routes of vaccine administration were used, and viral load and neutralizing antibody titers were measured at different time-points following vaccination. All 30 vaccinated animals developed a neutralizing antibody response to each of the four dengue serotypes, and only 3 of these animals had detectable serum viral RNA after challenge with wild-type dengue virus (DENV), suggesting protection of vaccinated animals to DENV infection. The vaccine induced statistically significant changes in 595 gene transcripts on days 1, 3, 5 and 7 as compared with baseline and placebo-treated animals. Genes involved in the type I interferon (IFN) response, including IFI44, DDX58, MX1 and OASL, exhibited the highest fold-change in transcript abundance, and this response was strongest following double dose and subcutaneous (versus intradermal) vaccine administration. In addition, modules of genes involved in antigen presentation, dendritic cell activation, and T cell activation and signaling were enriched following vaccination. Increased abundance of gene transcripts related to T cell activation on day 5, and the type I IFN response on day 7, were significantly correlated with the development of high neutralizing antibody titers on day 30.
  
  
  
  These results suggest that early transcriptional responses may be predictive of development of adaptive immunity to TDV vaccination in cynomolgus macaques, and will inform studies of human responses to dengue vaccines.
authors.affiliation: Department of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.
authors.forename: Fiona R
authors.initials: FR
authors.lastname: Strouts
authors.affiliation: Department of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Popper
authors.affiliation: Takeda Vaccines, Inc., Deerfield, Illinois, United States of America.
authors.forename: Charalambos D
authors.initials: CD
authors.lastname: Partidos
authors.affiliation: Takeda Vaccines, Inc., Deerfield, Illinois, United States of America.
authors.forename: Dan T
authors.initials: DT
authors.lastname: Stinchcomb
authors.affiliation: Takeda Vaccines, Inc., Deerfield, Illinois, United States of America.
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Osorio
authors.affiliation: Department of Microbiology and Immunology, Stanford University, Stanford, California, United States of America.|Department of Medicine, Stanford University, Stanford, California, United States of America.|Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America.
authors.forename: David A
authors.initials: DA
authors.lastname: Relman
mesh_terms: D056704:Adaptive Immunity / Q000235:genetics*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D017951:Antigen Presentation / Q000235:genetics; D003715:Dengue / Q000517:prevention & control* / Q000821:virology; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology; D020869:Gene Expression Profiling; D006801:Humans; D007370:Interferon Type I / Q000235:genetics; D011323:Primates; D065288:Serogroup; D015398:Signal Transduction / Q000235:genetics; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D014766:Viremia / Q000517:prevention & control
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053059:Dengue Vaccines; D007370:Interferon Type I; D014613:Vaccines, Attenuated